While glycemic control and the progression of complications can be effectively managed in HNF4A-MODY patients receiving long-term insulin therapy, the potential risks of hypoglycemic episodes, obesity, and atherosclerosis remain significant concerns. This evidence concerns the gene INS and obesity disorder.